Oral fosfomycin for treating lower urinary tract infections due to multidrug-resistant Escherichia coli in female adolescents

Polat M., Ozkaya-Parlakay A., TAPISIZ A., Kara S. S., YÜKSEL S.

Journal of Chemotherapy, vol.34, no.2, pp.97-102, 2022 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.1080/1120009x.2021.1955203
  • Journal Name: Journal of Chemotherapy
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.97-102
  • Keywords: Escherichia coli, female adolescents, Fosfomycin trometamol, lower urinary tract infections, multidrug-resistant, oral
  • Çanakkale Onsekiz Mart University Affiliated: No

Abstract

Fosfomycin trometamol (FT) has shown promising in vitro activity against multidrug-resistant (MDR) uropathogens; however, clinical data are limited in pediatric patients. We conducted a retrospective study to describe the clinical and microbiological outcomes of uncomplicated lower urinary tract infections (LUTIs) due to MDR Escherichia coli treated with oral FT in female adolescents. A total of 70 outpatients, with a median age of 13 years (range 12-16 years), were included. FT was initiated as definitive treatment of UTIs in all patients due to documented resistance against alternative oral agents. All patients received a single dose of 3 g oral FT. The post-treatment clinical and microbiological cure rates were 97% (68/70) and 94% (66/70), respectively. Only two (3%) patients reported mild, self-limited diarrhea. UTI relapse occurred in two (3%) patients. Our results suggest that oral FT might be an alternative option for outpatient treatment of uncomplicated LUTIs due to MDR E. coli in female adolescents.